| Literature DB >> 34066918 |
Ana P Marques1,2,3,4, Rosa Resende1,2,3,4, Diana F Silva1,2,3,4, Mariana Batista4,5, Daniela Pereira4,6,7, Brigite Wildenberg4,6,7, Sofia Morais4,6,7, António Macedo4,6,7,8, Cláudia Pais9, Joana B Melo1,4,6,9,10, Nuno Madeira4,6,7,8, Cláudia F Pereira1,2,4,6.
Abstract
This study aims to evaluate whether mitochondrial changes occur in the early stages of bipolar disorder (BD). Using fibroblasts derived from BD patients and matched controls, the levels of proteins involved in mitochondrial biogenesis and dynamics (fission and fusion) were evaluated by Western Blot analysis. Mitochondrial membrane potential (MMP) was studied using the fluorescent probe TMRE. Mitochondrial morphology was analyzed with the probe Mitotracker Green and mitophagy was evaluated by quantifying the co-localization of HSP60 (mitochondria marker) and LC3B (autophagosome marker) by immunofluorescence. Furthermore, the activity of the mitochondrial respiratory chain and the glycolytic capacity of controls and BD patients-derived cells were also studied using the Seahorse technology. BD patient-derived fibroblasts exhibit fragmented mitochondria concomitantly with changes in mitochondrial dynamics and biogenesis in comparison with controls. Moreover, a decrease in the MMP and increased mitophagy was observed in fibroblasts obtained from BD patients when compared with control cells. Impaired energetic metabolism due to inhibition of the mitochondrial electron transport chain (ETC) and subsequent ATP depletion, associated with glycolysis stimulation, was also a feature of BD fibroblasts. Overall, these results support the fact that mitochondrial disturbance is an early event implicated in BD pathophysiology that might trigger neuronal changes and modification of brain circuitry.Entities:
Keywords: bioenergetics; bipolar disorder; fibroblasts; mitochondrial biogenesis; mitochondrial dysfunction; mitophagy
Year: 2021 PMID: 34066918 PMCID: PMC8148531 DOI: 10.3390/biomedicines9050522
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059
Figure 1Mitochondrial morphology in BD patients’ fibroblasts. Mitochondrial morphology was analyzed by fluorescent microscopy using Mitotracker Green. (A) Representative confocal microscopy images of the mitochondrial network shown in green and Hoechst 33342-stained nuclei in blue (magnification, ×40). (B) Mitochondrial roundness, (C) mitochondrial aspect ratio, (D) mitochondrial form factor were determined through the analysis of the fluorescence of confocal microscopy images. Data are the mean ± SEM of 5 different individuals of each group. The experiments were carried out in duplicate and 5 images were analyzed. *** p < 0.001; **** p < 0.0001, significantly different from control group, as determined by Mann–Whitney non-parametric test.
Figure 2Fission/fusion machinery in BD patients’ fibroblasts. The levels of the mitochondrial fission proteins (A) Fis1 and (B) p-Drp1 and the mitochondrial fusion proteins (C) OPA1 (D) Mfn2 and (E) Mfn1, in fibroblasts from BD patients and control individuals were evaluated by Western blot analysis. Drp1 was used as the loading control for p-Drp1 (S616) and β-actin was used as loading control for the other proteins. The results were normalized to β-actin or Drp1 and expressed as mean ± SEM of 5 different control individuals and 3-4 BD patients. WB representative images correspond to BD and control samples analyzed on the same gel. * p < 0.05, significantly different from control group, as determined by Mann–Whitney non-parametric test.
Figure 3Mitochondrial biogenesis in BD patients’ fibroblasts. The protein levels of mediators of mitochondrial biogenesis (A) PGC1α (B), mtTFA and (C) NRF1 were evaluated in fibroblasts from BD patients and control individuals through Western blot analysis. β-actin was used as loading control. The results were normalized to β-actin and expressed as mean ± SEM of 5 different control individuals and 4 BD patients. WB representative images correspond to BD and control samples analyzed on the same gel. A Mann–Whitney non-parametric test was used to statistical analysis.
Figure 4Mitophagy-associated proteins in BD patients’ fibroblasts. Co-localization of LC3B (autophagosome marker) and HSP60 (mitochondrial marker) was evaluated by immunocytochemistry. (A) Representative confocal microscopy images of LC3B (red) and HSP60 (green) immunoreactivity and nuclei labelling with Hoechst 33,342 (blue) (magnification, ×40). LC3B and HSP60 co-localization (B) as well as LC3B staining (C) were quantified using the ImageJ software. The experiments were carried out in duplicate and 5 images were analyzed. The protein levels of p62 (D) were evaluated in fibroblasts from BD patients and control individuals through Western blot analysis. β-actin was used as loading control. The results were normalized to β-actin. The mitochondrial membrane potential (E) was assessed using the fluorescent probe TMRE. Basal fluorescence (excitation: 505 nm; emission: 525 nm) was measured using a microplate reader. Data are expressed as mean ± SEM of 5 different control individuals and 4 BD patients. WB representative images correspond to BD and control samples analyzed on the same gel. * p < 0.05, significantly different from control group, as determined by Mann–Whitney non-parametric test.
Figure 5Mitochondrial respiration and glycolytic capacity in BD patients’ fibroblasts. Oxygen consumption rate (OCR) was evaluated in fibroblasts from BD patients and age-matched controls. (A–F) Mitochondrial respiration was assessed by sequential addition of oligomycin, FCCP and rotenone/antimycin A by using a Seahorse XF24 flux analyzer. (A) Representative traces depicting the average of n = 5 controls and n = 3 BD patients-derived fibroblasts. (B) Basal mitochondrial respiration, (C) maximal O2 consumption and (D) ATP production values result from the subtraction of each parameter with the first value of OCR after rotenone+antimycin injection. Data are the mean ± SEM expressed in absolute values of five different control individuals and three BD patients after the correction with non-mitochondrial OCR provided by the injection of rotenone+antimycin. (E,F) Glycolytic capacity was assessed by sequential addition of oligomycin and 2-deoxyglucose (2-DG). (E) Representative traces and (F) glycolytic capacity. Data are the mean ± SEM expressed in absolute values of five different control individuals and 3 BD patients after the correction with non-glycolytic ECAR provided by the injection of 2-deoxyglucose. Experiments were carried out in duplicate. * p < 0.05; ** p < 0.01, significantly different from control group, as determined by Mann–Whitney non-parametric test.